Chapter 10. Lung Tumors

  1. Prof. Dr. Heike Allgayer PhD3,
  2. Prof. Dr. Helga Rehder4 and
  3. Prof. Dr. Simone Fulda5
  1. Sarah Danson1,
  2. M Dawn Teare2 and
  3. Penella Woll1

Published Online: 21 AUG 2009

DOI: 10.1002/9783527627523.ch10

Hereditary Tumors: From Genes to Clinical Consequences

Hereditary Tumors: From Genes to Clinical Consequences

How to Cite

Danson, S., Teare, M. D. and Woll, P. (2008) Lung Tumors, in Hereditary Tumors: From Genes to Clinical Consequences (eds H. Allgayer, H. Rehder and S. Fulda), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527627523.ch10

Editor Information

  1. 3

    University of Heidelberg and DKFZ (German Cancer Research Center) Heidelberg, Medical Faculty Mannheim, Chair of Experimental Surgery, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim, Germany

  2. 4

    Medical University Vienna, Department of Medical Genetics, Währinger Strasse 10, 1090 Wien, Austria

  3. 5

    Ulm University Children's Hospital, Eythstrasse 24, 89075 Ulm, Germany

Author Information

  1. 1

    University of Sheffield, Academic Department of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield, S10 2SJ, United Kingdom

  2. 2

    University of Sheffield, Mathematical Modelling and Genetic Epidemiology, The Medical School, Beech Hill Road, Sheffield, S10 2RX, United Kingdom

Publication History

  1. Published Online: 21 AUG 2009
  2. Published Print: 17 DEC 2008

ISBN Information

Print ISBN: 9783527320288

Online ISBN: 9783527627523

SEARCH

Keywords:

  • detoxification;
  • genome-wide association;
  • polymorphisms;
  • repair genes;
  • thoracic malignancies;
  • twins

Summary

Whilst the hereditary components of many tumors are well described, this is not the case for thoracic malignancies and much work is ongoing in this area. A strong family history is rare but there is increasing evidence that testing for polymorphisms, especially for genes involved in detoxification and DNA repair, may one day be used to identify those at risk of lung cancer. In those that develop lung cancer, polymorphism status could be combined with tumor characteristics to design customized treatment regimens.